Skip to main content
. 2023 Jan 7;29(1):126–143. doi: 10.3748/wjg.v29.i1.126

Figure 2.

Figure 2

Major sites of action of drugs currently used in the treatment of metabolic-associated fatty live disease. Various medications targeting comorbidities that coexist with metabolic-associated fatty live disease are used to treat symptomatic patients. The asterisk indicates adipocyte action is not shown. GLP-1RA: Glucagon-like insulinotropic peptide-1 receptor agonist; SGLT-2: Sodium glucose cotransporter-2.